KBC Group
VRDN icon

KBC Group’s Viridian Therapeutics VRDN Stock Holding History

KBC Group’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$34K Buy
+1,737
New +$51.6K ﹤0.01% 1773

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

KBC Group's VRDN Position: Q1 2026 in Review

KBC Group opened a new position in Viridian Therapeutics (VRDN) in Q1 2026: 1,737 shares worth $34K. The stake represents ﹤0.01% of the portfolio and ranks #1773 among its holdings.

225 funds tracked by Wall St. Rank hold VRDN as of Q1 2026.

  • KBC Group held 1,737 shares of Viridian Therapeutics worth $34K as of Q1 2026.
  • Viridian Therapeutics was a new KBC Group position in Q1 2026.
  • Viridian Therapeutics made up ﹤0.01% of KBC Group's portfolio in Q1 2026, its #1773 holding.
  • 225 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q1 2026.

Based on KBC Group's 13F filing for Q1 2026, filed 7 May 2026.